Source link : https://www.newshealth.biz/health-news/obinutuzumab-a-success-in-phase-3-trial-for-lupus-nephritis/
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo-controlled study. In the trial, 46.4% of patients in the obinutuzumab group had a complete renal response at 76 weeks compared with 33.1% of those in the standard therapy […]
Author : News Health
Publish date : 2025-02-17 07:18:44
Copyright for syndicated content belongs to the linked Source.
in Health